US General Anesthesia Drugs Market Size- By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
US General Anesthesia Drugs Market Introduction and Overview
According to SPER market research, ‘US General Anesthesia Drugs Market Size-By Route of Administration, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2033’state that the US General Anesthesia Drugs Market is predicted to reach USD 3.18 Billion by 2033 with a CAGR of 3.6%.
General Anaesthesia in the US A class of medications called drugs is used to cause anaesthesia. Generally speaking, they fall into three categories: sedatives, which help patients rest; neuromuscular blocking drugs, which paralyse muscles; and general anaesthetics, which cause anaesthesia.
Due to the burden on healthcare systems and the cancellation or postponement of elective surgeries, the COVID-19 pandemic is predicted to have a negative effect on the market for general anaesthesia drugs. Increased risks of post-operative complications and mortality were noted in a February 2023 Review for Medical and Pharmacological Sciences article for patients with recent or continuing COVID-19 infections. Anaesthesia use is made more difficult by possible drug interactions and the impossibility of a safe gap between COVID-19 therapy and surgery.
Scope of the Report:
Report Metric Details
Market size available for years 2019-2033
Base year considered 2022
Forecast period 2023-2033
Segments covered By Route of Administration, By End User
Regions covered
Central Region, North Region, South Region
Companies Covered
Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others
US General Anesthesia Drugs Market Key Segments Covered
By End User:Based on the End User, US General Anesthesia Drugs Market is segmented as; Ambulatory Surgery Centres, Hospitals.
By Region:This research also includes data for Central Region, North Region, South Region.
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER’s internal database
- 2.1.4. Premium insight from KOL’s
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 4.2. COVID-19 Impacts of the US General Anesthesia Drugs Market
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTER’s Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. US General Anesthesia Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in US General Anesthesia Drugs Market
- 7. US General Anesthesia Drugs Market, By Route of Administration (USD Million)
- 7.1. US General Anesthesia Drugs Market Value Share and Forecast, By Route of Administration, 2023-2033
- 7.2. Inhalational
- 7.2.1. Desflurane
- 7.2.2. Isoflurane
- 7.2.3. Nitrous Oxide
- 7.2.4. Sevoflurane
- 7.3. Intravenous
- 7.3.1. Benzodiazepines
- 7.3.2. Etomidate
- 7.3.3. Fentanyl
- 7.3.4. Ketamine
- 7.3.5. Methohexital Sodium
- 7.3.6. Propofol
- 7.3.7. Remifentanil
- 7.3.8. Others
- 8. US General Anesthesia Drugs Market, By End User (USD Million)
- 8.1. US General Anesthesia Drugs Market Value Share and Forecast, By End User, 2023-2033
- 8.2. Ambulatory Surgery Centres
- 8.3. Hospitals
- 9. US General Anesthesia Drugs Market Forecast, 2019-2033 (USD Million)
- 9.1. US General Anesthesia Drugs Market Size and Market Share
- 10. US General Anesthesia Drugs Market, By Route of Administration, 2019-2033 (USD Million)
- 10.1. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2019-2026)
- 10.2. US General Anesthesia Drugs Market Size and Market Share By Route of Administration (2027-2033)
- 11. US General Anesthesia Drugs Market, By End User, 2019-2033 (USD Million)
- 11.1. US General Anesthesia Drugs Market Size and Market Share By End User (2019-2026)
- 11.2. US General Anesthesia Drugs Market Size and Market Share By End User (2027-2033)
- 12. US General Anesthesia Drugs Market, By Region, 2019-2033 (USD Million)
- 12.1. US General Anesthesia Drugs Market Size and Market Share By Region (2019-2026)
- 12.2. US General Anesthesia Drugs Market Size and Market Share By Region (2027-2033)
- 12.3. Central Region
- 12.4. North Region
- 12.5. South Region
- 13. Company Profile
- 13.1. Abbott Laboratories
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
- 13.2. AbbVie
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
- 13.3. Akorn
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
- 13.4. AstraZeneca plc
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
- 13.5. Baxter International Inc.
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
- 13.6. Gilead Sciences, Inc
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
- 13.7. Heritage Pharmaceuticals Inc.
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
- 13.8. Novartis AG
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
- 13.9. Par Pharmaceutical
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
- 13.10. Pfizer Inc.
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
- 13.11. Others
- 14. List of Abbreviations
- 15. Reference Links
- 16. Conclusion
- 17. Research Scope
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook